Who are Vertex Pharmaceuticals's decision-makers?
Vertex Pharmaceuticals is led by Reshma Kewalramani. Sellers should map decisions across the executive sponsor, business-unit owner, procurement, legal, security, privacy, compliance, finance, clinical or scientific stakeholders, and implementation owners.
- CEO
- Reshma Kewalramani
- CFO/key exec
- Charles Wagner
- Founded
- 1989
- Employees
- 5,700+
- HQ
- Boston, MA
- Status
- Nasdaq: VRTX
- Reshma KewalramaniChief Executive Officer and PresidentCEO since 2020Leads Vertex's cystic fibrosis franchise and expansion into pain, sickle cell disease, beta thalassemia, and renal disease.
- Charles WagnerExecutive Vice President and Chief Financial OfficerCFO since 2019Oversees finance, strategy, and investor operations.
- David AltshulerChief Scientific OfficerCSO through planned 2026 transitionGuides R&D and pipeline strategy during Vertex's diversification.
- Carmen BozicExecutive Vice President, Global Medicines Development and Medical AffairsSenior medical leaderLeads clinical development and medical affairs.
Who leads Vertex Pharmaceuticals?
Vertex Pharmaceuticals's leadership team combines enterprise healthcare operations, finance, R&D, clinical, product, technology, legal, manufacturing, and commercial roles. The CEO and CFO set capital priorities, while business-unit leaders decide which operational problems become funded initiatives.
Who actually makes buying decisions at Vertex Pharmaceuticals?
Buying decisions usually start with a business-unit sponsor, then move through procurement, finance, legal, information security, privacy, compliance, quality, and implementation owners. Clinical, reimbursement, regulatory, or scientific stakeholders become essential whenever the purchase touches patient care, regulated data, clinical evidence, medical products, lab workflows, or payer/provider economics.
How is Vertex Pharmaceuticals organized as it scales?
Vertex Pharmaceuticals operates through product, therapeutic-area, regional, manufacturing, commercial, and corporate functions. That creates multiple entry points, but enterprise standards for security, privacy, compliance, contracting, vendor risk, and data governance can still control the final approval path.
As of June 2026.Sources:Vertex Pharmaceuticals leadershipVertex Pharmaceuticals annual reports
Vertex Pharmaceuticals — frequently asked questions
